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best and 12% at end. Changes in renal function and 
liver enzymes were not statistically signiﬁcant. There was
a signiﬁcant improvement in LDL and blood pressure
while on rosiglitazone. There were eight patients with ele-
vations of liver enzymes.
CONCLUSIONS: In routine Canadian clinical practice,
rosiglitazone is effective at lowering both FBG and
HbA1c signiﬁcantly over time and appear to be compa-
rable to, or better than, those reported for the established
oral agents. Many patients were able to reach improved
targets of HbA1c and FBG with no reported serious
adverse events. Further study is required to investigate the
beneﬁcial metabolic effects observed on blood pressure
and lipids.
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OBJECTIVE: Combination therapy with angiotensin-
converting enzyme inhibitors (ACE-I)/calcium channel
blocker (CCB) has been recommended for hypertensive
diabetics. This study assessed the cost-effectiveness of 
an ACE-I/non-dihydropyridine CCB (ACE-I/NDCCB:
Trandolapril/Verapamil or T/V) relative to an ACE-
I/dihydropyridine CCB (ACE-I/DCCB: Benazepril/
Amlodipine or B/A) for the treatment of patients with dia-
betes, who frequently also have hypertension.
METHODS: We have adapted a previously published
Markov model that simulated the disease progression of
a hypothetical cohort newly-diagnosed diabetes patients
towards end-stage renal disease (ESRD). The model was
developed from a payer perspective and estimated the dis-
counted drug and ESRD costs and quality adjusted life
years (QALYs) over a 3-year, 5-year and lifetime time
horizon. The baseline analysis conservatively assumed
that all patients, regardless of treatment received, pro-
gressed from normoalbuminuria to microalbuminuria
(progression rate = 0.011), to gross proteinuria (progres-
sion rate = 0.026), and to ESRD (progression rate =
0.034). Given clinical evidence demonstrating greater
reductions in baseline proteinuria with T/V than with B/A
(urinary albumin excretion -65% versus -25%, respec-
tively), the least conservative scenario assumed that
patients receiving T/V would progress less rapidly than
patients receiving B/A.
RESULTS: In the baseline analysis, T/V resulted in lower
net costs than B/A. The cost advantage per hypertensive
diabetic is $92, $141 and $743 in favor of T/V over a
three-year, ﬁve-year and lifetime time frame respectively.
When the most extreme clinical difference is assumed,
T/V treatment results in $168, $313 and $2,293 in net
savings per diabetic over the respective time periods while
also providing a small net beneﬁt in QALYs (.000632,
.0018, .063 QALYs per patient).
CONCLUSIONS: From a payer perspective, T/V is cost-
saving relative to B/A for the management of hyperten-
sives with diabetes under both scenarios. These savings
are driven by the lower cost of drug and the reduced
resources required for ESRD treatment.
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OBJECTIVES: Onset of Type 2 diabetes (T2D) can be
delayed by lifestyle changes and/or medications. Forecasts
predict an epidemic of new cases of T2D as the popula-
tion ages, and modern lifestyles become increasingly
unhealthy. T2D patients have >double mortality rates and
higher treatment costs of matched non-diabetics. A model
was developed to assess acceptable cost limits for a gen-
eral population-targeted program aimed at reducing the
incidence of T2D by 10%.
METHODS: A Markov model simulated the incidence of
and increased direct medical costs and mortality associ-
ated with T2D. Data were derived from published
sources. Costs and life expectancy (LE) calculated (dis-
counted at 3% p.a.). Analyses assessed the maximum
costs/person a payer could outlay to achieve a 10% reduc-
tion in T2D incidence a) without increasing the health-
care budget, and b) remaining within an attractive
incremental cost-effectiveness (ICER) <$50,000/life year
gained. A health insurance perspective was taken. 
Sensitivity analysis identiﬁed parameters with important
impacts on outcomes.
RESULTS: A diabetes prevention intervention aimed at a
general population with mean age 50 years that reduces
incidence of T2D by 10% would improve LE by 0.05
years per person. Up to a cost of $55/year/person, the
program would result in overall cost savings due avoid-
ance of higher costs associated with T2D. The ICER 
of the program would be <$50,000 at a cost of
$250/person/year. Sensitivity analysis revealed that age of
target population, effectiveness of intervention, incidence
of diabetes, and increase in mortality with diabetes have
a large inﬂuence on the results.
CONCLUSIONS: Diabetes prevention programs aimed
at a general population could be cost saving or cost-
effective if the costs of the program do not exceed limits
identiﬁed. In other, higher-risk populations, such as
glucose intolerant or racial sub-groups, where the inci-
dence of diabetes and effects of intervention are greater,
these cost limits are could be higher.
